ArticleChinese medicine2026
Gambogic acid induces cell death via covalent binding with PRDX1 to regulate ER stress and autophagy.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGambogic acid (GA) is a natural bioactive compound derived from Garcinia hanburyi Hook. F, has proven anticancer activity and is currently in Phase II clinical trials for the treatment of cancer. However, the molecular mechanisms and targets underlying GA's anti-renal cell carcinoma effects remain unclear.
methodsCCK-8 assay evaluated kidney cancer cell viability via formazan formation. Flow cytometry identified apoptotic cells using characteristic fluorescence signals. Western blotting assessed autophagy- and apoptosis-related protein expression through extraction, SDS-PAGE, transfer, and antibody detection. JC-1 assay determined mitochondrial health by measuring red-to-green fluorescence ratio in kidney cancer cells. The production of reactive oxygen species (ROS) was quantified through CM-H2DCFDA staining. Additionally, a range of techniques, such as proteomics, activity-guided protein profiling (ABPP), and cellular thermal stability assays (CETSA), were employed to ascertain the molecular targets involved.
resultsGA induces cell death by inducing ER stress and modulating autophagy. GA-induced autophagy is involved in ER stress activation. Importantly, GA-induced ER stress and subsequently cell death is caused by increased ROS levels. Mechanistic studies show that peroxiredoxin-1 (PRDX1), a key antioxidant enzyme, is a directly covalent binding target of GA, and overexpression of PRDX1 mitigates GA-induced ROS production and subsequently cell death.
conclusionThe study identified PRDX1 is a potential directly covalent binding protein of gambogic acid, and elucidated its mechanism for inducing cell death that involving in ROS-mediated ER stress and autophagy regulation. The results obtained offer fresh perspectives on the mechanisms underlying the cytotoxic effects induced by gambogic acid, further suggesting that PRDX1 may represent a promising candidate for targeted therapy in the development of novel anticancer agents, notably for the treatment of kidney cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.